TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Inspira Technologies Oxy BHN ( (IINN) ) is now available.
On December 3, 2025, Inspira Technologies announced a strategic expansion of its blood laboratory capabilities, marking a significant step in its evolution towards cutting-edge diagnostic technologies. This expansion involves moving to a larger facility, increasing recruitment of specialized personnel, and upgrading research instrumentation. The new laboratory is expected to enhance sample processing capacity and integrate advanced diagnostic technologies, positioning Inspira for accelerated growth and addressing high-value medical needs. This development is seen as a foundation for aggressive business growth, potentially generating long-term value for patients and shareholders.
The most recent analyst rating on (IINN) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Inspira Technologies Oxy BHN stock, see the IINN Stock Forecast page.
Spark’s Take on IINN Stock
According to Spark, TipRanks’ AI Analyst, IINN is a Underperform.
The overall stock score reflects significant financial instability, as indicated by ongoing losses and reliance on external funding. The technical analysis shows bearish sentiment, with the stock under pressure. Valuation is challenging due to negative earnings and lack of dividend yield, making the stock less appealing to investors.
To see Spark’s full report on IINN stock, click here.
More about Inspira Technologies Oxy BHN
Inspira Technologies Oxy B.H.N. Ltd. is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The company offers the FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S. It is also developing the INSPIRA ART500 system for oxygenation while patients remain awake and spontaneously breathing. Additionally, Inspira is advancing HYLA, a proprietary blood sensor platform for continuous, non-invasive monitoring. With multiple cleared products and a growing IP portfolio, Inspira is positioned as a significant player in the life-support and MedTech industry.
Average Trading Volume: 271,540
Technical Sentiment Signal: Sell
Current Market Cap: $32.95M
For a thorough assessment of IINN stock, go to TipRanks’ Stock Analysis page.